PolicyLatest
Pharma lobbyist steps down amid GLP-1 drug discussions
A prominent pharma lobbyist is stepping down, impacting industry dynamics. The conversation also includes insights on genes and GLP-1 drugs, highlighting ongoing developments in the pharmaceutical sector.
0 upvotes
What happened
A prominent pharma lobbyist is stepping down, impacting industry dynamics.
Why it matters
The conversation also includes insights on genes and GLP-1 drugs, highlighting ongoing developments in the pharmaceutical sector.